Ireland
--:--IST
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

National and Kapodistrian University of Athens clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our Belgium, Czechia, Portugal and EU (CTIS) registers with National and Kapodistrian University of Athens as lead sponsor. Synced 3 Oct 2026
3Current trials
2Recruiting now
1Drug in these trials
4Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

National and Kapodistrian University of Athens is the lead sponsor of 3 current clinical trials in our Belgium, Czechia, Portugal and EU (CTIS) registers. 2 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Anifrolumab. The most-studied condition is Aortic Valve Disease.

ClinicalTrials.gov trials by status

  • Recruiting2100%

Trials by phase

  • Not applicable150%
  • Observational150%
01

Clinical trials sponsored by National and Kapodistrian University of Athens

2 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Innovative Ovarian Cancer Biomarker Assays
NCT07693894 · ClinicalTrials.gov ↗ · Ovarian Cancer
Observational Recruiting 2026-08 Czechia, Portugal
Rapid Atrial Pacing After TAVI to Predict Pacemaker Implantation
NCT06189976 · ClinicalTrials.gov ↗ · Aortic Valve Disease, Transcatheter Aortic Valve Implantation, TAVI
Not applicable Recruiting 2024-03 Belgium

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

National and Kapodistrian University of Athens in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with National and Kapodistrian University of Athens as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). The AnifAPS trial.
2025-520918-64-00 · CTIS ↗ · Immune System Diseases
Phase 2 Ongoing Greece
03

Drugs in National and Kapodistrian University of Athens trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

04

Conditions in National and Kapodistrian University of Athens trials

4 conditions
Aortic Valve Disease1Transcatheter Aortic Valve Implantation1TAVI1Ovarian Cancer1
05

By trial register

RegisterTrialsRecruiting
Clinical trials in Belgium11
Clinical trials in Czechia11
Clinical trials in Portugal11
EU register (CTIS)1—

A trial with sites in more than one country appears in each of those registers.

06

Other sponsors in Aortic Valve Disease

SponsorTrials
Shanghai MicroPort CardioFlow Medtech1
Medtronic Cardiac Surgery1

Sponsors with the most current trials registered for this condition.

07

Questions about National and Kapodistrian University of Athens trials

How many clinical trials does National and Kapodistrian University of Athens sponsor?

National and Kapodistrian University of Athens is the lead sponsor of 2 current trials on ClinicalTrials.gov in our Belgium, Czechia and Portugal registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 3 October 2026. Completed and withdrawn studies are not counted.

Are National and Kapodistrian University of Athens trials recruiting?

Yes. 2 of its 2 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is National and Kapodistrian University of Athens testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Anifrolumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.